Steve E. Krognes, Director at Denali Therapeutics Inc. (DNLI), sold 2,750 shares at $17.29 ($48K) on 2024-02-13, disclosed to the SEC on 2024-02-15.
Seasonal sale ($48k) by Director — this insider has traded DNLI in February in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| Filing → |
| DNLI | SELL | 2025-01-08 | $139K | — | Filing → |
| DNLI | SELL | 2025-01-03 | $608K | — | Filing → |
| DNLI | SELL | 2024-10-02 | $871K | — | Filing → |